Meropenem: adverse event reports filed with FDA

15,365

reports as suspect product

0.1% of all reports · about 683 a year

1,505

reports, 12 months to June 2026

1,814 in the 12 months before

97.6%

marked serious by the reporter

94.1% across the class

27.8%

record death among outcomes, as reported

4,277 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Meropenem reports recording the termmedian drug in penem antibacterial

1. Drug ineffectivethe medicine did not work as expected20.1%3,086
2. Off label useused for a purpose or in a way not on the label10.9%1,677
3. Condition aggravatedthe condition being treated got worse5.3%807
4. Pyrexiafever4.9%760
5. Septic shockshock arising from infection4.5%695
6. Multiple organ dysfunction syndromeseveral organs failing4.4%681
7. Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement4%613
8. Drug resistance3.7%565
9. Drug interactionan interaction between medicines3.5%536
10. Acute kidney injurysudden loss of kidney function3.3%507
11. Thrombocytopenialow platelets3.3%502
12. Sepsisa severe body-wide response to infection3.2%489
13. Rashskin rash2.9%445
14. Diarrhoealoose or frequent stools2.7%417
15. Pneumonialung infection2.7%410
16. Drug ineffective for unapproved indication2.6%405
17. Product use in unapproved indicationused for a purpose not on the label2.6%393
18. Respiratory failurethe lungs could not supply enough oxygen2.6%393
19. Pathogen resistance2.3%358
20. Toxic epidermal necrolysisa severe skin reaction with peeling2.2%340
21. Dyspnoeashortness of breath2.2%333
22. Pancytopenialow counts of all blood cells2.1%328
23. Neutropenialow neutrophils, a type of white blood cell2.1%327
24. Eosinophilia2.1%316
25. Anaemialow red blood cells2%305
26. Renal failurekidney failure1.8%273
27. Candida infectionthrush, a yeast infection1.7%265
28. Febrile neutropeniafever with low white blood cells1.7%264
29. Rash maculo-papulara rash of flat and raised spots1.7%263
30. Hypotensionlow blood pressure1.7%257

Top 30 of 1,728 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the penem antibacterial class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 23,429 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 15.6% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 15,365 reports.

Drugs most often listed in the same reports

Other products listed in reports where Meropenem is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the penem antibacterial class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Meropenem as a suspect or interacting product; reports listing it only as a concomitant medication (17,163) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.